Pulmonx (LUNG) Stock Price, News & Analysis

+0.10 (+1.35%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
235,799 shs
Average Volume
569,601 shs
Market Capitalization
$289.05 million
P/E Ratio
Dividend Yield
Price Target

Pulmonx MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
111.1% Upside
$15.83 Price Target
Short Interest
3.23% of Float Sold Short
Dividend Strength
News Sentiment
Insider Trading
Selling Shares
$460,144 Sold Last Quarter
Proj. Earnings Growth
From ($1.79) to ($1.77) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.69 out of 5 stars

Medical Sector

624th out of 909 stocks

Surgical & Medical Instruments Industry

68th out of 96 stocks

LUNG stock logo

About Pulmonx Stock (NASDAQ:LUNG)

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

LUNG Stock Price History

LUNG Stock News Headlines

Pulmonx (LUNG) to Release Earnings on Wednesday
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Navigating 6 Analyst Ratings For Pulmonx
Pulmonx Taps Mehul Joshi as Finance Chief
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
LUNG Apr 2024 12.500 call
LUNG Apr 2024 7.500 put
LUNG May 2024 7.500 put
LUNG Aug 2024 10.000 put
LUNG Apr 2024 10.000 call
LUNG Aug 2024 20.000 call
Wells Fargo Downgrades Pulmonx (LUNG)
Pulmonx Full Year 2023 Earnings: Beats Expectations
Wells Fargo downgrades Pulmonx on management uncertainty
Pulmonx just downgraded at Wells Fargo, here's why
See More Headlines
Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Confirmed)
Fiscal Year End

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$68.68 million
Book Value
$3.09 per share


Free Float
Market Cap
$289.05 million
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

LUNG Stock Analysis - Frequently Asked Questions

Should I buy or sell Pulmonx stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LUNG shares.
View LUNG analyst ratings
or view top-rated stocks.

What is Pulmonx's stock price target for 2024?

6 Wall Street analysts have issued 12-month price objectives for Pulmonx's stock. Their LUNG share price targets range from $12.00 to $18.00. On average, they predict the company's share price to reach $15.83 in the next year. This suggests a possible upside of 111.1% from the stock's current price.
View analysts price targets for LUNG
or view top-rated stocks among Wall Street analysts.

How have LUNG shares performed in 2024?

Pulmonx's stock was trading at $12.75 at the beginning of 2024. Since then, LUNG stock has decreased by 41.2% and is now trading at $7.50.
View the best growth stocks for 2024 here

When is Pulmonx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our LUNG earnings forecast

How can I listen to Pulmonx's earnings call?

Pulmonx will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Pulmonx's earnings last quarter?

Pulmonx Co. (NASDAQ:LUNG) issued its quarterly earnings results on Wednesday, February, 21st. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.02. The business earned $19.30 million during the quarter, compared to analyst estimates of $18.24 million. Pulmonx had a negative net margin of 88.60% and a negative trailing twelve-month return on equity of 46.63%. The business's quarterly revenue was up 25.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.38) EPS.

What guidance has Pulmonx issued on next quarter's earnings?

Pulmonx issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $81.0 million-$84.0 million, compared to the consensus revenue estimate of $78.9 million.

When did Pulmonx IPO?

Pulmonx (LUNG) raised $100 million in an IPO on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Who are Pulmonx's major shareholders?

Pulmonx's stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, John Mckune, Richard Ferrari and Scientific Corp Boston.
View institutional ownership trends

How do I buy shares of Pulmonx?

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LUNG) was last updated on 4/24/2024 by Staff

From Our Partners